It's actually $142m in rev V bad debt $34m.... from my quick research its at 23% of revenue and rising from previous financial year.
Can you explain how you chose this? I like to hear both sides so appreciate your opinion.
- Forums
- ASX - By Stock
- APT
- Ann: FY2018 Appendix 4E and Annual Report
Ann: FY2018 Appendix 4E and Annual Report, page-53
Featured News
Add APT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online